Cancer Epidemiology最新文献

{"title":"Right versus left lung cancer: Findings from the Japanese cancer registry database","authors":"Nobuaki Michihata ,&nbsp;Aya Washio ,&nbsp;Yoshihide Terada ,&nbsp;Naoto Kaneko ,&nbsp;Yohko Nakamura ,&nbsp;Yoshitaka Hippo","doi":"10.1016/j.canep.2025.102870","DOIUrl":"10.1016/j.canep.2025.102870","url":null,"abstract":"<div><div>Laterality, which is the biological difference between the left and right sides of the body, has been identified as a potential factor in cancer development and progression. Previous studies have suggested that lung cancer incidence may differ between the right and left lungs, influenced by anatomical, genetic, and environmental factors. In this study, we investigated the relationship among lung cancer laterality, incidence, and prognosis. This cohort study used data from the Chiba Prefecture Cancer Registry (2013–2020) and included 36,502 patients with primary lung cancer. Patient characteristics were compared between patients with right- and left-sided lung cancers. Kaplan-Meier survival curves, log-rank tests, and Cox proportional hazards models were used to assess laterality differences in mortality, adjusted for age, sex, summary stage, histological type, and other covariates. Right-sided lung cancer was more prevalent (60 %) than left-sided (40 %). The Cox model revealed a slightly higher mortality rate for right-sided lung cancer than for left-sided cancer (hazard ratio [HR]: 1.05, 95 % confidence interval [CI]: 1.02–1.08, <em>p</em> = 0.003). Sex-stratified analysis showed a higher mortality risk for male with right-sided cancer (HR: 1.08, 95 % CI: 1.04–1.12, <em>p</em> &lt; 0.001) but no significant laterality difference in female. The higher prevalence of right-sided lung cancer may be due to anatomical differences and genetic factors, such as the higher prevalence of the L858R mutation. Although the clinical impact of laterality differences is minimal, these findings provide insights into lung cancer pathogenesis and may contribute to advancing personalized medicine.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"97 ","pages":"Article 102870"},"PeriodicalIF":2.4,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144366398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Squamous cell carcinoma: Dynamics and prediction of relative survival revealed using model-based period analysis","authors":"Suzheng Zheng ,&nbsp;Jinrong Zhang ,&nbsp;Hai Yu ,&nbsp;Wai Chi Lau ,&nbsp;Ming Chen ,&nbsp;Hongtao Cheng ,&nbsp;Hua Xian ,&nbsp;Wai-kit Ming ,&nbsp;YAU SUN LAK ,&nbsp;Leong Nga Cheng ,&nbsp;Qiqi Zhao ,&nbsp;Wenhui Chen ,&nbsp;Hui Huang ,&nbsp;Jun Lyu ,&nbsp;Liehua Deng","doi":"10.1016/j.canep.2025.102860","DOIUrl":"10.1016/j.canep.2025.102860","url":null,"abstract":"<div><h3>Background</h3><div>Squamous cell carcinoma (SCC) is a common and aggressive malignancy, often diagnosed at advanced stages with a high tendency for lymph node metastasis, leading to poor prognosis. Understanding current survival rates is crucial, as analyzing SCC survival trends helps identify prognostic factors, evaluate treatment effectiveness, and guide clinical decision-making to improve patient outcomes.</div></div><div><h3>Methods</h3><div>Period analyses were used to examine the relative survival rates and trends in patients with SCC from the Surveillance, Epidemiology, and End Results (SEER) database (2000–2019). In addition, generalized linear models based on data stratified by age, race, sex, area, stage, and subtype in the SEER database were created to forecast the 5-year relative survival of SCC patients from 2020 to 2024.</div></div><div><h3>Results</h3><div>During the observation period, different degrees of increase were reflected in the 5-year relative survival rates of overall SCC and most SCC subtypes, with the most significant improvement in small cell nonkeratinizing squamous cell carcinoma, from 38.4 % to 68.8 %. The comprehensive 5-year relative survival rates for SCC during the respective intervals of 2000–2004, 2005–2009, 2010–2014, and 2015–2019 were recorded as 44.1 %, 46.7 %, 47.8 %, and 51.5 %, sequentially. In most subtypes, women had slightly higher survival rates than men. In addition, survival rates were significantly higher in urban areas than in rural areas, lower in the elderly than in the young, and higher in white patients than in nonwhite patients, with significantly lower survival rates for SCC with distant metastases.</div></div><div><h3>Conclusion</h3><div>During the two decades from 2000 to 2019, we observed a general trend of gradual improvement in the survival rate of SCC patients. This upward trend is expected to continue during the five-year period 2020–2024, according to projections. Through an in-depth assessment of the status of SCC patients over the past two decades, we can better predict the future trend of SCC. This not only provides a scientific basis for the relevant authorities, but also provides strong support for the development of effective tumor prevention and control strategies.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"97 ","pages":"Article 102860"},"PeriodicalIF":2.4,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144366397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Child and adolescent/young adult cancer incidence and survival for Māori in Aotearoa New Zealand","authors":"Jason Gurney ,&nbsp;Kirsten Ballantine ,&nbsp;Annie Chiang ,&nbsp;Anna Davies ,&nbsp;Chris GCA Jackson ,&nbsp;Jonathan Koea ,&nbsp;James Stanley ,&nbsp;Scott Macfarlane","doi":"10.1016/j.canep.2025.102868","DOIUrl":"10.1016/j.canep.2025.102868","url":null,"abstract":"<div><div>Cancer does not occur equally within populations, and this is also true within children and young adults. In this study we draw-together comprehensive national health record data to describe cancer incidence and survival for Māori children and adolescents/young adults (AYA), and compare this with the experience of Europeans. All incident cases of cancer diagnosed between 2007 and 2019 among those aged less than 25 years old at the time of diagnosis were extracted from the New Zealand Cancer Registry. Cancer incidence numbers and rates were compared between Māori and European children/AYA. We also used Kaplan-Meier (1, 3 and 5-year cancer-specific survival) and Cox proportional hazards models (hazard ratios) to compare survival outcomes between these groups. We found differences between Māori and Europeans in terms of propensity toward certain types of child/AYA cancers: Māori are more likely to be diagnosed with poorer-prognosis cancers (like CNS/brain) and less likely to be diagnosed with good-prognosis cancers (like Hodgkin’s lymphoma and melanoma). Māori are less likely to survive their cancer once diagnosed even after adjusting for differences in cancer type, with the extent of survival disparities differing depending on the cancer under investigation, noting that these cancer-specific observations were prone to precision problems due to low absolute numbers of deaths. Further quantitative and qualitative research on the drivers of survival disparities, particularly in the context of access to early diagnosis and treatment, could usefully inform actions aimed at improving survival for Māori and addressing disparities.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"97 ","pages":"Article 102868"},"PeriodicalIF":2.4,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144366941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Regional disparities in incidence and outcomes of invasive ductal carcinoma of the breast among Asian and Pacific Islander women in the United States","authors":"Kailee Bunte ,&nbsp;Bianca Ituarte ,&nbsp;Gowri Warikoo ,&nbsp;Pedro Morales-Ramírez","doi":"10.1016/j.canep.2025.102861","DOIUrl":"10.1016/j.canep.2025.102861","url":null,"abstract":"<div><h3>Background</h3><div>Asian women have experienced a disproportionate increase in breast cancer incidence over the past four decades when compared to patients of other races. We aim to determine the variation of incidence and survival rates for Asian women based on their residential status by region of the United States.</div></div><div><h3>Methods</h3><div>The Surveillance, Epidemiology and End Results (SEER) 17-State database was used to identify cases of ductal carcinoma and its subtypes (ICD-O-3/3 codes: 8500, 8521, 8503, 8507, 8514, 8522, 8523; C50.0–50.9) among Asian and Pacific Islander (API) women during 2000–2020. Chi square tests were used for comparison of clinical and socioeconomic variables and Kolmogorov-Smirnov and Kruskal Wallis tests were used to assess differences between mean time to treatment and diagnosis. Incidence was analyzed via Joinpoint Regression Software with Kaplan-Meier survival curves for evaluation of survival by region, measured in months. Multivariate Cox proportional hazards regression identified independent predictors of survival. All statistical analyses were conducted using SPSS Version 29.0.2, with significance at p &lt; 0.05.</div></div><div><h3>Results</h3><div>The West represented the largest incidence over the 20-year study period with 89.6 per 100,000 (95 % CI: 88.9–90.2). There were notable differences in both 5-year and 10-year survival rates with the south having the largest decline, dropping from 84 % at 5 years and 54 % at 10 years. This is despite the south being found to have the shortest time to treatment, 0.97 months (95 % CI: 0.95–0.99; p = 0.009). Multivariate Cox regression showed API women in the South had a 24 % increased risk of mortality compared to those in the West (aHR 1.244, 95 % CI: 1.176–1.315; p &lt; 0.001).</div></div><div><h3>Conclusions</h3><div>The results of this study demonstrate significant disparities in incidence, treatment patterns, and survival outcomes amongst API women by residential status.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"97 ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144329602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comorbidity burden and risk of second primary non-breast cancer in breast cancer survivors","authors":"Amrita Mukherjee ,&nbsp;Zheng Gu ,&nbsp;Lie Hong Chen ,&nbsp;Rowan T. Chlebowski ,&nbsp;Arnold L. Potosky ,&nbsp;Reina Haque","doi":"10.1016/j.canep.2025.102867","DOIUrl":"10.1016/j.canep.2025.102867","url":null,"abstract":"<div><h3>Background</h3><div>Breast cancer survivors have an increased risk of second primary cancers. However, the impact of comorbidity burden on risk of second primary non-breast cancer in breast cancer survivors is under-studied. We evaluated the association of comorbidity burden with risk of second primary non-breast cancer in breast cancer survivors.</div></div><div><h3>Methods</h3><div>In this retrospective cohort study, breast cancer patients aged ≥ 18 years diagnosed with in-situ, local, or regional first primary breast between 2008 and 2020 at Kaiser Permanente Southern California, were included. Patients were followed until 12/31/2021. Rates of second primary non-breast cancer were reported. Association of Elixhauser comorbidity index (ECI) and second primary cancer was reported using Cox proportional hazards regression.</div></div><div><h3>Results</h3><div>Of 37,222 female breast cancer survivors included, 1701 (4.6 %) survivors developed second primary non-breast cancers during a median (interquartile range) follow-up of 5.2 (2.8–8.6) years. Nearly one-third (32.3 %) of the survivors had ECI score 3 + ; 22.6 % had ECI score 1–2; rest 27.0 % had zero ECI score. Incidence rates of second cancers were 561, 739, and 1064 per 100,000 person-years in survivors with ECI= 0, 1–2, and 3 + , respectively. In multivariable analyses, compared to survivors with ECI= 0, survivors with ECI scores 1–2 and 3 + had higher risk of second primary non-breast cancer [unadjusted HR (95 % CI): 1.32 (1.16–1.50) and 1.88 (1.65–2.14), respectively]. Higher risk of second primary non-breast cancer persisted in survivors with ECI score 3 + in the adjusted model [adjusted HR (95 % CI): 1.24 (1.08–1.43)].</div></div><div><h3>Conclusion</h3><div>Comorbidity burden appears to be correlated with an increased risk of second primary non-breast cancers in breast cancer survivors. Active surveillance and effective management of modifiable comorbidities may help in reducing second primary cancer risk in breast cancer survivors.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"97 ","pages":"Article 102867"},"PeriodicalIF":2.4,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144322340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thyroid cancer in West Java: It’s not all papillary and pretty","authors":"Kiki Akhmad Rizki ,&nbsp;Rantapina Kurniasari ,&nbsp;Monty Priosadewo ,&nbsp;Maman Abdurrahman ,&nbsp;Raden Yohana Azhar ,&nbsp;Dodi Lumbal Gaol ,&nbsp;Rupita Sari Endangena Sitanggang ,&nbsp;Zuldi Erdiansyah ,&nbsp;Prapanca Nugraha ,&nbsp;Arrayyan Muhammad ,&nbsp;Etis Primastari","doi":"10.1016/j.canep.2025.102869","DOIUrl":"10.1016/j.canep.2025.102869","url":null,"abstract":"<div><h3>Background</h3><div>Thyroid cancer is the most common endocrine malignancy in children and adults. The rising incidence of thyroid cancer, which remains poorly understood, raises the need to evaluate whether this increase will lead to higher mortality and more aggressive disease. This study aimed to describe the characteristics of thyroid cancer at the largest hospital in West Java and to examine the relationships between these characteristics.</div></div><div><h3>Methods</h3><div>This was an observational study. The subjects were patients with thyroid tumors in the oncology surgery division of a tertiary hospital in West Java, Indonesia, from January 2017 to December 2022. A total of 3414 subjects were included in the study. The characteristics of the thyroid tumors were extracted from medical records.</div></div><div><h3>Results</h3><div>The results showed that the mean age of the participants was 47 years, thyroid tumors were more common in women (82.9 %), and tumor location was frequently found on the right side (38.6 %) and over 90 % of cases showed no lymph node metastasis. Univariate analysis confirmed significant associations between histology and patient sex, tumor location, size, and nodal status (all p &lt; 0.05), with very few subcentimeter tumors and higher metastatic rates in papillary (30.3 %) and medullary (37.5 %) carcinomas.</div></div><div><h3>Conclusion</h3><div>Thyroid cancer, particularly papillary thyroid carcinoma, was prevalent in the study population, with significant associations between histopathology, sex, tumor size, and lymph node metastasis. These findings highlight the important of using risk-based FNA and selective surgical referral to exclude low-risk microcarcinomas. Adherence to these strategies will mitigate overdiagnosis and unnecessary surgery.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"97 ","pages":"Article 102869"},"PeriodicalIF":2.4,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144297416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The patient journey of head neck cancer from primary care to diagnosis – A retrospective cohort study in the Netherlands","authors":"Naomi Reimes ,&nbsp;Sarah ER Bailey ,&nbsp;Jasmin B. Post ,&nbsp;Josephina G. Kuiper ,&nbsp;Benjamin P. van Nieuwenhuizen ,&nbsp;Jetty A. Overbeek ,&nbsp;Stefan M. Willems ,&nbsp;Robert P. Takes","doi":"10.1016/j.canep.2025.102865","DOIUrl":"10.1016/j.canep.2025.102865","url":null,"abstract":"<div><h3>Objective</h3><div>There are currently no data available on the referral landscape of head and neck cancer (HNC) patients from first visit to a general practitioner (GP) to diagnosis in the Netherlands. Since primary care is a key setting to reduce time to diagnosis (TTD), this study aimed to describe the healthcare pathway of HNC patients from first GP visit to diagnosis.</div></div><div><h3>Study design</h3><div>This study was a population-based case-control study among patients with HNC matched to a non-HNC control group.</div></div><div><h3>Setting</h3><div>The data collection period was between 2013 and 2020, the setting was in the Netherlands.</div></div><div><h3>Methods</h3><div>Patient and tumor characteristics were assessed at index date. The healthcare pathway between start date and index date was assessed, as well as TTD for cases, which was stratified by patient and tumor characteristics.</div></div><div><h3>Results</h3><div>The final study population consisted of 9565 persons, of which 1913 HNC patients and 7652 matched non-HNC controls. Cases were most often male (67 %), median age was 66 years. HNC patients had more often a smoking and drinking history compared to controls (p &lt; 0.0001). Cases had more GP visits, received more medication, were ordered more laboratory tests and had more referrals to a specialist, compared to controls (all p &lt; 0.05). The overall mean (±standard deviation) TTD was 43.0 (±34.3) weeks, and was affected by gender, tumor location, and number of GP visits.</div></div><div><h3>Conclusion</h3><div>This is the first study that reported the demographics and healthcare use from first GP visit to diagnosis in the Netherlands. Future research should focus on identifying opportunities for earlier diagnosis.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"97 ","pages":"Article 102865"},"PeriodicalIF":2.4,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144297417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A population-based analysis of cancer survival in Fujian Province, southeast China during 2021–2023","authors":"Zhisheng Xiang ,&nbsp;Jingyu Ma ,&nbsp;Yeying Wen ,&nbsp;Yongtian Lin ,&nbsp;Yongying Huang ,&nbsp;Linrong Wu ,&nbsp;Yan Zhou ,&nbsp;Chuanben Chen","doi":"10.1016/j.canep.2025.102866","DOIUrl":"10.1016/j.canep.2025.102866","url":null,"abstract":"<div><h3>Background</h3><div>Population-based survival data is commonly used to evaluate the effectiveness of cancer prevention and treatment. This study aims to assess the 5-year relative survival of patients with cancer in Fujian Province, southeastern China, between 2021 and 2023.</div></div><div><h3>Methods</h3><div>The new cases of cancer in 25 cancer registries in Fujian Province from 2016 to 2021 were included in this study, and patients’ survival status was followed up until March 1, 2024. The hybrid method was used to calculate cancer relative survival by gender, region and age (2021–2023), and results were standardized according to International Cancer Survival Standards Weights.</div></div><div><h3>Results</h3><div>There were 184,216 patients were included in the study after quality control, including 101,338 males and 82,878 females. The 5-year relative survival for all cancers combined was 51.7 %, and the age-standardized 5-year relative survival was 43.8 % in 2021–2023. The age-standardized 5-year relative survival was higher in females than males (52.7 % and 36.3 %). The survival in urban was higher than that in rural areas (49.3 % and 37.9 %). The three types of cancer with the highest survival in males were thyroid (94.5 %), testicular (77.7 %), bladder (69.1 %). In females, thyroid cancer (94.9 %), breast cancer (77.6 %) and bladder cancer (72.1 %) were the three cancers with the highest survival. Most cancer survival was higher in females than in males. The relative survival decreased with age, the highest survival was 79.5 % in the age group under 45 years old and the lowest survival was 21.8 % in the age 75 and above.</div></div><div><h3>Conclusions</h3><div>The cancer survival rates in Fujian Province have reached the goal of Healthy China 2030, but there is still a gap with high survival areas. To narrow this gap, more targeted interventions are needed to further improve cancer survival.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"97 ","pages":"Article 102866"},"PeriodicalIF":2.4,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144297418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer in persons diagnosed with facial nerve paresis: A hospital-based cohort study in Denmark","authors":"Holly Elser ,&nbsp;Dóra Körmendiné Farkas ,&nbsp;Lindsay J. Collin ,&nbsp;Malene Risager Lykke ,&nbsp;Cecilia Hvitfeldt Fuglsang ,&nbsp;Henrik Toft Sørensen","doi":"10.1016/j.canep.2025.102863","DOIUrl":"10.1016/j.canep.2025.102863","url":null,"abstract":"<div><h3>Background</h3><div>Neoplasms can compress or infiltrate the facial nerve, leading to facial nerve paresis or palsy (FNP). As evidence regarding cancers outside the head, neck, and nervous system in persons initially diagnosed with FNP remains limited, we examined the overall and site-specific cancer rates among all patients diagnosed with FNP in Denmark over a 29-year study period.</div></div><div><h3>Methods</h3><div>We conducted a hospital-based cohort study in Denmark, 1994–2022, identifying FNP from inpatient, outpatient, or emergency room visits. We computed absolute risks (AR), and age- and sex-standardized incidence ratios (SIR) with corresponding 95 % confidence intervals (CIs) for all cancers, cancer groups, and site-specific cancers diagnosed &lt;1 year and ≥1 after FNP diagnosis.</div></div><div><h3>Results</h3><div>There were 27,147 recorded diagnoses of FNP. For cancers diagnosed &lt;1 year after FNP, the AR was 1.67 % (95 %CI: 1.53,1.83) and the SIR was 2.62 (95 %CI: 2.38,2.87) with strong associations for cancers of the nervous system (SIR=14.7, 95 %CI: 12.1,17.7) and head and neck (SIR = 8.37, 95 %CI: 6.41,10.7). For cancers diagnosed ≥1 year after FNP, the AR was 20.2 % (95 %CI: 18.0,22.6) and the SIR was 1.08 (95 %CI: 1.04,1.13) with persistent associations for cancers of the salivary gland (SIR=2.43, 95 %CI: 1.11,4.62), brain (SIR = 1.48, 95 %CI: 1.16,1.86), spinal cord, cranial nerves, and other parts of the central nervous system (SIR = 1.83, 95 %CI: 1.22,2.62), liver (SIR = 2.02, 95 %CI: 1.50,2.65), and anus (SIR = 1.94, 95 %CI: 1.09,3.20).</div></div><div><h3>Conclusion</h3><div>Rates of local cancers remained persistently elevated among persons diagnosed with FNP as compared with the Danish general population, as did rates of distant cancers implying a key role for metastatic disease as an underlying cause of FNP. Research that explores these associations by cancer stage may yield additional insight into these observed associations.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"97 ","pages":"Article 102863"},"PeriodicalIF":2.4,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144263935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Socioeconomic inequalities in prostate cancer mortality in Canada: Three decades trend analysis","authors":"Mohammad Hajizadeh ,&nbsp;Loukman Ghouti ,&nbsp;Grace Johnston","doi":"10.1016/j.canep.2025.102862","DOIUrl":"10.1016/j.canep.2025.102862","url":null,"abstract":"<div><div>In Canada, prostate cancer is the most diagnosed cancer among males and the third leading cause of cancer-related deaths accounting for 10 % of all cancer fatalities in males. This study examines socioeconomic inequalities in prostate cancer mortality among the Canadian male population. Using a dataset compiled at the census division level (n = 280) from sources including the Canadian Vital Statistics Deaths database and the Canadian Census of Population for the years 1992, 1996, 2001, 2006, and 2016, as well as the 2011 National Household Survey, we investigated socioeconomic inequalities in mortality rates in prostate cancer among Canadian men from 1990 to 2019. We applied the age-standardized Concentration index (C) to measure inequalities in mortality linked to income and education levels. Trend analysis was conducted to evaluate the changes over time of these inequalities. The crude prostate cancer mortality in Canada was 24.82 per 100,000 males over the study period and decreased significantly over time. The age-standardized C showed a higher concentration of prostate cancer mortality among low-income males in 1999, 2001 and 2005. Additionally, we observed a significantly higher concentration of mortality among less-educated groups, particularly in the more recent study years. Trend analysis revealed a growing concentration of prostate cancer mortality among less-educated males over the study period. Our study revealed an increasing concentration of PCa mortality among low-educated male populations. Socioeconomic inequalities in PCa mortality may be partly attributable to variations in treatment access across different geographic regions and opportunistic screening among higher socioeconomic status males in the more recent study years.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"97 ","pages":"Article 102862"},"PeriodicalIF":2.4,"publicationDate":"2025-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144240604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}